Gemcitabine in the treatment of bladder cancer

Christopher W. Ryan, Nicholas J. Vogelzang

    Research output: Contribution to journalReview articlepeer-review

    2 Scopus citations


    New agents are available for the treatment of metastatic transitional cell carcinoma of the bladder. In the US, the combination of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) remains the standard chemotherapy regimen for advanced bladder cancer. Gemcitabine (2′,2″-difluorodeoxycytidine [dFdCD is a relatively new agent with a favourable toxicity profile that has demonstrated activity against a number of solid tumours in both preclinical and clinical studies. Single-agent gemcitabine has shown activity in bladder cancer in both pretreated and chemotherapy-naïve patients. The combination of gemcitabine plus cisplatin is a regimen with significant activity and moderate toxicity in bladder cancer patients. A randomised trial of gemcitabine plus cisplatin versus M-VAC has completed accrual but has not yet been reported. New combination studies of gemcitabine with other chemotherapy agents, including the taxanes, are ongoing. 2000

    Original languageEnglish (US)
    Pages (from-to)547-553
    Number of pages7
    JournalExpert Opinion on Pharmacotherapy
    Issue number3
    StatePublished - Mar 2000


    • Antimetabolites
    • Bladder cancer
    • Cisplatin
    • Clinical trials
    • Gemcitabine
    • Transitional cell carcinoma

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)

    Fingerprint Dive into the research topics of 'Gemcitabine in the treatment of bladder cancer'. Together they form a unique fingerprint.

    Cite this